Olympus Corporation (TYO:7733)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.99T -2.3% |
| Revenue (ttm) | 1.01T +1.3% |
| Net Income | 68.17B -42.2% |
| EPS | 61.20 -40.5% |
| Shares Out | 1.06B |
| PE Ratio | 30.60 |
| Forward PE | 21.36 |
| Dividend | 30.00 (1.60%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 6,011,700 |
| Average Volume | 5,581,980 |
| Open | 1,858.00 |
| Previous Close | 1,875.00 |
| Day's Range | 1,852.00 - 1,904.00 |
| 52-Week Range | 1,302.50 - 2,168.00 |
| Beta | n/a |
| RSI | 69.63 |
| Earnings Date | May 12, 2026 |
About Olympus
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific S... [Read more]
Financial Performance
In fiscal year 2026, Olympus's revenue was 1.01 trillion, an increase of 1.34% compared to the previous year's 997.33 billion. Earnings were 68.17 billion, a decrease of -42.16%.
Financial StatementsNews
Olympus shares drop over 5% after CEO resigns over drug allegation
Shares of Japanese camera giant Olympus Corp fell on Monday after the company announced the resignation of its chief executive officer over a drug allegation. In a notice, Olympus said that it receive...
Olympus CEO steps down amid illegal drug purchase allegations; endoscope manufacturer's shares drop 7%
Olympus Corp shares fell over 7% on Monday, marking the steepest intraday decline in nearly three months, following the announcement that CEO Stefan Kaufmann had resigned from all roles effective imme...
Olympus upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded Olympus to Buy from Neutral with a price target of 2,850 yen, up from 2,300 yen. Having performed well below the stock market average since November 2022,…
Olympus Corp. of the Americas to Host Panel Discussion on Lung Cancer Screening Guidelines and Eligibility
Lung Cancer Awareness Month panel will examine who is at risk for lung cancer and what they need to know about the screening process and treatment options CENTER VALLEY, Pa. , Nov. 9, 2023 /PRNewswire...
Olympus Issues Request to Discontinue Use of UHI-4 Insufflator Unit, Except in Cases Where No Alternative is Available
CENTER VALLEY, Pa. , Oct. 27, 2023 /PRNewswire/ -- Olympus Corporation has announced a field corrective action in the U.S. to address complaints of adverse events from over insufflation during use of ...
Healthcare creating more opportunities for tech investors, says Harris Financial's Jamie Cox
Jamie Cox, Harris Financial Group managing partner, joins 'The Exchange' to discuss investment opportunities in medical devices, the intersection of healthcare and technology, and top picks in the med...
Olympus Corp. of the Americas Named Founders Award Winner
Company recognized for administrative professionals' career advancement initiative, OA3 CENTER VALLEY, Pa. , July 6, 2023 /PRNewswire/ -- Olympus Corp. of the Americas (OCA) announced today that it re...
Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
CENTER VALLEY, Pa. , July 3, 2023 /PRNewswire/ -- Olympus Corporation has announced a voluntary field corrective action to address complaints of endobronchial combustion occurring when laser-compatibl...
Olympus reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of Olympus with a Neutral rating and 2,700 yen price target. The analyst sees downside risk to consensus estimates in fiscal 2023 and 2024. The firm…
Olympus nearing deal to sell microscope unit for over $2 billion - sources
Japan's Olympus Corp is close to selling its microscope unit to a private equity firm in a deal that could fetch more than 300 billion yen ($2.2 billion), three people with direct knowledge of the mat...